Printer Friendly

CYTOGEN ACQUIRES RIGHTS TO UNILEVER CANCER PROGRAM

 PRINCETON, N.J., Feb. 9 /PRNewswire/ -- Cytogen Corporation (NASDAQ: CYTO) announced today that it has acquired worldwide rights to the cancer-based monoclonal antibody research and development program of Unipath Ltd., the Unilever medical products company.
 As part of this agreement, CYTOGEN has exclusive rights to five monoclonal antibodies which target breast, colorectal and ovarian tumors, four of which originated from the Imperial Cancer Research Fund. The agreement also grants CYTOGEN rights to the relevant Unilever patents, technology, scientific and clinical data as well as state-of- the-art technology for humanizing monoclonal antibodies. Two of the monoclonal antibodies have undergone clinical evaluation and have subsequently been humanized. Encouraging results from these trials have been noted in the diagnosis and treatment of ovarian carcinoma.
 In commenting on this agreement, George W. Ebright, CYTOGEN's Chairman and CEO, stated, "The acquisition of this program is significant in that the monoclonal antibodies and technology obtained are extremely complementary to the CYTOGEN product development program, and allow us to broaden our business in the cancer imaging and therapy markets. CYTOGEN has established itself as the leader in the field of monoclonal antibody-based imaging by developing and obtaining approval for OncoScint CR/OV, two cancer products that are the first
of their kind and are of substantial benefit to cancer patients. We believe this accomplishment was of key significance to Unilever in selecting CYTOGEN as the recipient of this program."
 Specific terms of the agreement were not disclosed.
 CYTOGEN is a biopharmaceutical company engaged in the development of products utilizing monoclonal antibodies for the targeted delivery of diagnostic and therapeutic substances directly to sites of disease. CYTOGEN uses its patented and proprietary antibody "linker" technology primarily to develop specific cancer diagnostic imaging and cancer therapeutic products.
 /delval/
 -0- 2/9/93
 /CONTACT: Mary Beals, director of corporate communications of Cytogen, 609-987-8221/
 (CYTO)


CO: Cytogen Corporation; Unipath Ltd. ST: New Jersey IN: MTC SU: TNM

JS -- PH002 -- 4487 02/09/93 09:08 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 9, 1993
Words:325
Previous Article:STANDARD & POOR'S STOCK PRICE INDEX -- OPENING, TUESDAY, FEB. 9 /PRN/
Next Article:EPA ANNOUNCES DELETION OF FLORIDA SUPERFUND SITE FROM NATIONAL LIST OF HAZARDOUS WASTE SITES
Topics:


Related Articles
CYTOGEN AND CYTORAD INITIATE CLINICAL TRIALS OF CANCER THERAPY AGENT
CYTOGEN AND CHIRON EXPAND EUROPEAN MARKETING AGREEMENT
CYTOGEN CORPORATION ANNOUNCES THIRD QUARTER RESULTS
CYTOGEN AND CYTORAD ANNOUNCE EXPANDED AGREEMENT
CYTOGEN WELCOMES MICHAEL R. KURMAN AS DIRECTOR OF CANCER THERAPEUTICS, CLINICAL INVESTIGATIONS
CYTOGEN LICENSES RIGHTS TO TARGETING TECHNOLOGY
CYTOGEN SIGNS AGREEMENT WITH THE IMPERIAL CANCER RESEARCH TECHNOLOGY AND CONFIRMS THIRD QUARTER RESULTS
CYTOGEN STOCKHOLDERS APPROVE MERGER WITH CELLCOR
Cytogen Corporation and Mayor Rudy Giuliani to Ring in Prostate Cancer Awareness Month with NASDAQ Opening Bell Ceremony.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters